Structure, stability, and antiplatelet activity of O-acyl derivatives of salicylic acid and lipophilic esters of acetylsalicylate

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 476-489

  Zavodnik, Ilya B ^a,c   Lapshina, Elena ^a   Sudnikovich, Elena ^a   Boncler, Magdalena ^b   Luzak, Bogusława ^b   Rózalski, Marcin ^b   Helińska, Magdalena ^b   Watała, Cezary ^b  

^a INSTITUTE OF BIOCHEMISTRY   (Belarus)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c YANKA KUPALA STATE UNIVERSITY OF GRODNO   (Belarus)

Author keywords

Acetylsalicylic acid; Lipophilic esters of acetylsalicylate; O acyl derivatives of salicylic acid; Platelet aggregation; Platelet proteinacylation; Thromboxane generation

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; PADGEM PROTEIN; SALICYLIC ACID DERIVATIVE; THROMBOXANE;

ADULT; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DETERMINATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; NORMAL HUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ASPIRIN; DRUG STABILITY; ESTERS; HUMANS; MOLECULAR STRUCTURE; P-SELECTIN; PLATELET AGGREGATION; PROTEIN BINDING; SALICYLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOXANES;

EID: 67651172921     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70089-1     Document Type: Article

References (29)

1. Becker H, Berger W, Domschke G, Fanghanel E, Faust Ju, Fischer M, Gentz F et al.: Practical Approach to Organic Chemistry (German), VEB Deutscher Verlag der Wissenschaften, Berlin, 1976.
2. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J, Wilk R et al.: Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta, 2007, 1770, 1651-1659.
3. Casadebaig F, Dupin JP, Gravier D, Hou G, Daret D, Bernard H, Larrue J et al.: Action of some salicylate derivatives on in vitro platelet aggregation. Inhibitory and inhibition antagonistic effects. Thromb Res, 1991, 64, 631-636.
4. Catella F, Healy D, Lawson JA, FitzGerald GA: 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA, 1986, 83, 5861-5865.
5. Dembo M, Glushko V, Aberlin ME, Sonenberg M: A method for measuring membrane microviscosity using pyrene excimer formation. Application to human erythrocyte ghosts. Biochim Biophys Acta, 1979, 552, 201-211.
6. Dodge JT, Mitchell C, Hanahan DJ: The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys, 1963, 100, 119-130.
7. Dupin JP, Gravier D, Casadebaig F, Boisseau MR, Bernard H: Acetoxy benzene derivatives: in vitro antiaggregant activity. Farmaco [Sci], 1986, 41, 934-941.
8. Dupin JP, Gravier D, Casadebaig F, Boisseau MR, Bernard H: Relationship between structure and activity of aspirin-related compounds on the inhibition of in vitro platelet aggregation. Farmaco [Sci], 1986, 41, 205-214.
9. Erkoc S, Erkoc F, Keskin N: Theoretical investigation of melatonin and its hydroxy isomers. J Mol Struct (Theochem), 2002, 587, 73-79.
10. Gund P, Shen TY: A model for the prostaglandin synthetase cyclooxygenation site and its inhibition by antiinflammatory arylacetic acids. J Med Chem, 1977, 20, 1146-1152.
11. Hilgetag G, Martini A: Weygand-Hilgetag. Preparative Organic Chemistry (German), 3rd edn., Johann Ambrosius Barth (Verlag), Leipzig, 1964.
12. Hung DY, Mellick GD, Anissimov YG, Weiss M, Roberts MS: Hepatic structure-pharmacokinetic relationships: the hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Br J Pharmacol, 1998, 124, 1475-1483.
13. Hung DY, Mellick GD, Masci PP, Whitaker AN, Whitehouse MW, Roberts MS: Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats. J Lab Clin Med, 1998, 132, 469-477.
14. Hung DY, Mellick GD, Prankerd RJ, Roberts MS: Synthesis, identification, characterization, stability, solubility, and protein binding of ester derivatives of salicylic acid and diflunisal. Int J Pharm, 1997, 153, 25-39.
15. Jeffery J, Hobbs L, Jornvall H: Glucose-6-phosphate dehydrogenase from Saccharomyces cerevisiae: characterization of a reactive lysine residue labeled with acetylsalicylic acid. Biochemistry, 1985, 24, 666-671.
16. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL: Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem, 1994, 269, 13207-13215.
17. Lellouche F, Fradin A, Fitzgerald G, Maclouf J: Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins, 1990, 40, 297-310.
18. McKee SA, Sane DC, Deliargyris EN: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost, 2002, 88, 711-715.
19. Mehler EL, Gerhards J: Interaction model for antiinflammatory action of benzoic and salicylic acids and phenols. Int J Quantum Chem, 1989, 35, 205-209.
20. Murphy RC, FitzGerald GA: Current approaches to estimation of eicosanoid formation in vivo. Adv Prostaglandin Thromboxane Leukot Res, 1994, 22, 341-348.
21. Nocun M, Ulicna O, Muchova J, Durackova Z, Watala C: French maritime pine bark extract (Pycnogenol®) reduces thromboxane generation in blood from diabetic male rats. Biomed Pharmacother, 2007.
22. Salvetti F, Buttinoni A, Cesarini R: Relationships between a hydrophobic cyclooxygenase site model and indoprofen structure. Eur J Med Chem, 1981, 16, 81-90.
23. Santana L, Teijeira M, Uriarte E, Teran C, Linares B, Villar R, Laguna R et al.: AM1 theoretical study, synthesis and biological evaluation of some benzofuran analogues of anti-inflammatory arylalkanoic acids. Eur J Pharm Sci, 1999, 7, 161-166.
24. Sashidhar RB, Capoor AK, Ramana D: Quantitation of epsilon-amino group using amino acids as reference standards by trinitrobenzene sulfonic acid. A simple spectrophotometric method for the estimation of hapten to carrier protein ratio. J Immunol Methods, 1994, 167, 121-127.
25. Shimokawa T, Smith WL: Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem, 1992, 267, 12387-12392.
26. Vane J: Towards a better aspirin. Nature, 1994, 367, 215-216.
27. Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res, 2003, 110, 255-258.
28. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J: Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med, 2005, 83, 148-158.
29. Zavodnik I, Lapshina E, Bryszewska M: Effects of free fatty acids on the lipid and protein components of erythrocyte membrane. Memb Cell Biol, 1996, 5, 537-546.